Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review
Acting on the renin–angiotensin–aldosterone system, angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are mechanisms of some of the most prescribed medications in the world. In addition to their routine use for the treatment of hypertension, such agents have...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | JID Innovations |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667026723000577 |
| _version_ | 1797454306213888000 |
|---|---|
| author | Trenton Greif Mouaz Alsawas Alexander T. Reid Vincent Liu Larry Prokop M. Hassan Murad Jennifer G. Powers |
| author_facet | Trenton Greif Mouaz Alsawas Alexander T. Reid Vincent Liu Larry Prokop M. Hassan Murad Jennifer G. Powers |
| author_sort | Trenton Greif |
| collection | DOAJ |
| description | Acting on the renin–angiotensin–aldosterone system, angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are mechanisms of some of the most prescribed medications in the world. In addition to their routine use for the treatment of hypertension, such agents have gained attention for their influence on the angiotensin receptor pathway in fibrotic skin disorders, including scars and keloids. To evaluate the current level of evidence supporting the use of these agents, a systematic review related to ACE-Is/ARBs and cutaneous scarring was conducted. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from database inception through January 26, 2022. Two independent reviewers identified eligible studies for inclusion and extracted data. Data were insufficient for meta-analysis and are presented narratively. Of 461 citations identified, seven studies were included (199 patients). The studies included two randomized clinical trials, one comparative observation study, and four case reports. All the included studies reported statistically significant improvement in cutaneous scarring in patients using ACE-Is/ARBs compared with that in those treated with placebo/control using various outcome measures such as scar size and scar scales. However, much of the literature on this subject to date is limited by study design. |
| first_indexed | 2024-03-09T15:35:23Z |
| format | Article |
| id | doaj.art-c4fea5f0bedc41068b1ddd199ab24298 |
| institution | Directory Open Access Journal |
| issn | 2667-0267 |
| language | English |
| last_indexed | 2024-03-09T15:35:23Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JID Innovations |
| spelling | doaj.art-c4fea5f0bedc41068b1ddd199ab242982023-11-26T05:14:21ZengElsevierJID Innovations2667-02672023-11-0136100231Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic ReviewTrenton Greif0Mouaz Alsawas1Alexander T. Reid2Vincent Liu3Larry Prokop4M. Hassan Murad5Jennifer G. Powers6Department of Dermatology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA; Correspondence: Trenton Greif, Department of Dermatology, University of Iowa Carver College of Medicine, 200 Hawkins Drive, 40025 Pomerantz Family Pavilion, Iowa City, Iowa 52242-1089, USA.Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA; Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota, USADepartment of Dermatology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USADepartment of Dermatology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA; Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USAMayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USAMayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota, USADepartment of Dermatology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USAActing on the renin–angiotensin–aldosterone system, angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are mechanisms of some of the most prescribed medications in the world. In addition to their routine use for the treatment of hypertension, such agents have gained attention for their influence on the angiotensin receptor pathway in fibrotic skin disorders, including scars and keloids. To evaluate the current level of evidence supporting the use of these agents, a systematic review related to ACE-Is/ARBs and cutaneous scarring was conducted. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from database inception through January 26, 2022. Two independent reviewers identified eligible studies for inclusion and extracted data. Data were insufficient for meta-analysis and are presented narratively. Of 461 citations identified, seven studies were included (199 patients). The studies included two randomized clinical trials, one comparative observation study, and four case reports. All the included studies reported statistically significant improvement in cutaneous scarring in patients using ACE-Is/ARBs compared with that in those treated with placebo/control using various outcome measures such as scar size and scar scales. However, much of the literature on this subject to date is limited by study design.http://www.sciencedirect.com/science/article/pii/S2667026723000577 |
| spellingShingle | Trenton Greif Mouaz Alsawas Alexander T. Reid Vincent Liu Larry Prokop M. Hassan Murad Jennifer G. Powers Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review JID Innovations |
| title | Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review |
| title_full | Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review |
| title_fullStr | Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review |
| title_full_unstemmed | Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review |
| title_short | Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review |
| title_sort | targeting the angiotensin pathway in the treatment of cutaneous fibrosis a systematic review |
| url | http://www.sciencedirect.com/science/article/pii/S2667026723000577 |
| work_keys_str_mv | AT trentongreif targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT mouazalsawas targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT alexandertreid targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT vincentliu targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT larryprokop targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT mhassanmurad targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview AT jennifergpowers targetingtheangiotensinpathwayinthetreatmentofcutaneousfibrosisasystematicreview |